CLAIMS

~~What is claimed is:~~

1. ~~A method of treating type 1 diabetes in a human subject, comprising administering to the subject a pharmaceutical composition comprising~~ Use of an amylin analog at a therapeutically effective dose:

    (i) of at least 5 μg per kilogram of the subject per day; or

    (ii) that is at or greater than the ED75 dose of the amylin analog, in the preparation of a composition for the treatment of type I diabetes in a human subject.

2. The ~~method~~ use of claim 1, further comprising continuously maintaining a concentration of the amylin analog in the subject that is at or greater than the EC75 dose of the amylin analog.

3. The ~~method~~ use of claim 1 or claim 2, comprising continuous administration of the amylin analog.

4. The ~~method~~ use of claim 1 or claim 2, comprising continuous administration of the amylin analog via an implantable drug delivery device.

5. The ~~method~~ use of claim 4, wherein the implantable drug delivery device is an osmotic drug delivery device.

6. The ~~method~~ use of claim 1 or claim 2, comprising continuous administration of the amylin analog via a non-implantable drug delivery device.

7. The ~~method~~ use of claim 1 or claim 2, comprising continuous administration of the amylin analog via once weekly injection.

8. The ~~method~~ use of claim 1 or claim 2, wherein the amylin analog is pramlintide.

9. The ~~method~~ use of claim 1 or claim 2, wherein the amylin analog is compound A2 (SEQ ID NO:2).

10. The ~~method~~ use of claim 1 or claim 2, further comprising separate administration of an insulin.